Welcome to our dedicated page for Compass Pathways news (Ticker: CMPS), a resource for investors and traders seeking the latest updates and insights on Compass Pathways stock.
COMPASS Pathways plc reports biotechnology developments centered on COMP360, its proprietary synthetic psilocybin treatment candidate for serious mental health conditions, with treatment-resistant depression as the primary disclosed focus. News commonly covers clinical data, FDA and UK regulatory designations, NDA submission and review activity, and the company's work on delivery models for psychedelic treatment in clinical settings.
Recurring updates also include financial results and business highlights, investor conference participation, collaborations with psychiatry and care-delivery organizations, healthcare provider training initiatives, and equity compensation actions under Nasdaq rules. As an ADR-listed issuer, CMPS news can reflect parent-company operating updates and American Depositary Share-related corporate actions.
Compass Pathways has appointed Lori Englebert as Chief Commercial Officer, effective July 8, 2024. Lori joins from Axsome Therapeutics, where she was instrumental in the company's transition from clinical to commercial stage. Her experience includes commercializing CNS-focused assets at Axsome and Amgen. This appointment follows Teri Loxam as CFO and Dr. Michael Gold as Chief R&D Officer earlier this year. CEO Kabir Nath highlights the strengthened leadership team as important for navigating phase 3 trials and potential regulatory approval of COMP360, a psilocybin treatment for treatment-resistant depression.
Compass Pathways plc announced its first quarter 2024 financial results and key business highlights, including positive phase 2 COMP360 data in PTSD, on track phase 3 pivotal program in TRD, new commercial collaborations, appointment of Michael Gold as Head of R&D, and financial updates. The company's cash position was $262.9 million as of March 31, 2024.
Compass Pathways plc (Nasdaq: CMPS) reported top-line results from an open-label phase 2 study evaluating the safety and tolerability of COMP360 psilocybin treatment in 22 patients with PTSD. The study showed durable improvement in symptoms, with a significant reduction in the mean CAPS-5 total score and Sheehan Disability Scale (SDS) score. The administration of COMP360 was well-tolerated, with high response and remission rates observed. The results suggest a potential clinically meaningful benefit for patients with PTSD and open up possibilities for further research.
Compass Pathways plc (CMPS) partners with Mindful Health Solutions (MHS) to develop a cost-effective delivery model for COMP360 psilocybin treatment for treatment-resistant depression. This collaboration aims to understand potential approaches to deliver COMP360 in different care settings. MHS, a top behavioral health care provider in the US, will work with Compass to research patient pathways, therapist training needs, treatment rooms, and reimbursement considerations for psychedelic treatments. The goal is to make innovative treatments accessible to patients living with depression.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.